



Election/Amend B/
EXT 5 / # 10
3.4.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Tosato et al.

Art Unit: 1642

Application No. 09/807,148

Filed: April 5, 2001

For: USE OF CALRETICULIN AND
CALRETICULIN FRAGMENTS TO INHIBIT
ENDOTHELIAL CELL GROWTH AND
ANGIOGENESIS, AND SUPPRESS TUMOR
GROWTH

Examiner: Natalie A. Davis, Ph.D.

Date: February 13, 2003

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents
referred to as being attached or enclosed herewith are
being deposited with the United States Postal Service
on February 13, 2003 as First Class Mail in an envelope
addressed to: COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231.

[Signature]
Susan Alpert Siegel, Ph.D.
Agent for Applicant

RECEIVED

FEB 26 2003

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

This amendment is submitted in response to the Office action dated September 5, 2002, for which a one-month period for reply was set. Applicants petition for a five-month extension of time and submit the required fee, making a response due on or before March 5, 2003. Please amend the application as follows:

In the claims:

1. (Once amended) A method of inhibiting endothelial cell growth, comprising:
contacting an endothelial cell with a polypeptide comprising an amino
acid sequence at least 90% homologous to an amino acid sequence as set forth in SEQ ID NO: 2,
or a therapeutically effective fragment thereof,
thereby inhibiting endothelial cell growth.
2. (Once amended) The method of claim 1, wherein the therapeutically effective
fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6.